Viral drug resistance
The baseline and post-baseline RSV L-gene sequencing data were available for 40/78 and 13/33 patients in the lumicitabine and placebo groups, respectively, in the MAD phase of Study 1. Data were similarly available for all patients in the lumicitabine (n = 4) and placebo (n = 3) groups in Study 2.At the last evaluable on-treatment time point with sequencing data available, none of the patients in the lumicitabine groups, either in the MAD phase of Study 1 or in Study 2, had emerging amino acid substitutions at the 4 lumicitabine resistance-associated L-protein amino acid positions 628, 789, 795, or 796.